EcoDrugPlus

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSJJAG00000000137
Gene Symbol: GSK3A
3 Cross references
260 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSJJAG00000010506
Gene Symbol: GSK3B
3 Cross references
241 Possible Orthologues:

Glycoprotein Vi Platelet

Ensembl ID : ENSJJAG00000003429
Gene Symbol: GP6
3 Cross references
135 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSJJAG00000015514
Gene Symbol: GNRHR
3 Cross references
454 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSJJAG00000007770
Gene Symbol: GHRHR
3 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSJJAG00000022390
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSJJAG00000013368
Gene Symbol: GUCY1A1
3 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSJJAG00000018592
Gene Symbol: GUCY1A2
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSJJAG00000014626
Gene Symbol: GUCY1B1
3 Cross references
209 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class A Member 1

Ensembl ID : ENSJJAG00000018152
Gene Symbol: HSP90AA1
2 Cross references
208 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSJJAG00000018744
Gene Symbol: HSP90AB1
3 Cross references
205 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha Pseudogene

Ensembl ID : ENSJJAG00000022601
Gene Symbol: LOC101596040
1 Cross references
203 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).